Business Description
Boundless Bio Inc
NAICS : 541713
SIC : 2833
ISIN : US10170A1007
Total Employee Number:
28Description
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.92 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.56 | |||||
Debt-to-EBITDA | -0.81 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 5 | |||||
3-Year EPS without NRI Growth Rate | 7.5 | |||||
3-Year FCF Growth Rate | 10.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 21.97 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.92 | |||||
9-Day RSI | 63.48 | |||||
14-Day RSI | 67.66 | |||||
3-1 Month Momentum % | 22.12 | |||||
6-1 Month Momentum % | 5.34 | |||||
12-1 Month Momentum % | 16.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.87 | |||||
Quick Ratio | 9.87 | |||||
Cash Ratio | 9.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | -44.15 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -50.49 | |||||
ROA % | -33.43 | |||||
ROIC % | -115.59 | |||||
3-Year ROIIC % | -43.17 | |||||
ROC (Joel Greenblatt) % | -126.4 | |||||
ROCE % | -38.51 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.62 | |||||
Price-to-Tangible-Book | 0.63 | |||||
EV-to-EBIT | -0.16 | |||||
EV-to-EBITDA | -0.16 | |||||
EV-to-FCF | -0.2 | |||||
| Price-to-Net-Current-Asset-Value | 1.35 | |||||
| Price-to-Net-Cash | 1.41 | |||||
Earnings Yield (Greenblatt) % | -625 | |||||
FCF Yield % | -87.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BOLD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Boundless Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.5 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 82.09 | ||
| 14-Day RSI | 67.66 | ||
| 14-Day ATR ($) | 0.142335 | ||
| 20-Day SMA ($) | 2.12075 | ||
| 12-1 Month Momentum % | 16.95 | ||
| 52-Week Range ($) | 0.9612 - 2.79 | ||
| Shares Outstanding (Mil) | 22.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Boundless Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Boundless Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 117 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 25 days | ||
| General meeting for 2026 | 2026-06-15 11:00 | 1.41 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 1.53 (-3.77%) | ||
| Leerink Global Healthcare Conference | 2026-03-11 11:20 | 1.15 (-0.86%) | ||
| Annual report for 2025 | 2026-03-09 | 1.13 (+0.89%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 1.13 (+0.89%) | ||
| Guidance call for 2026 | 2026-02-12 15:00 | 1.11 (-1.77%) | ||
| Piper Sandler 37(th) Annual Healthcare Conference | 2025-12-03 09:30 | 1.09 (-2.68%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 1.30 (-3.70%) |
Show
Entries
Boundless Bio Inc Frequently Asked Questions
What is Boundless Bio Inc(BOLD)'s stock price today?
The current price of BOLD is $2.42. The 52 week high of BOLD is $2.79 and 52 week low is $0.96.
When is next earnings date of Boundless Bio Inc(BOLD)?
The next earnings date of Boundless Bio Inc(BOLD) is 2026-08-05 Est..
Does Boundless Bio Inc(BOLD) pay dividends? If so, how much?
Boundless Bio Inc(BOLD) does not pay dividend.
Guru Commentaries on NAS:BOLD
No articles.
Press Release
Articles on Boundless Bio Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers